Pantesin for healthy blood lipid support

Pantesin® is a high-quality pharmaceutical-grade form of Pantethine (an active form of Vitamin B5). Pantethine forms the reactive component of Coenzyme A (CoA) and the acyl-carrier protein (ACP). CoA and ACP are extensively involved in carbohydrate, lipid and amino acid metabolism. In addition to possessing the metabolic activity of pantothenic acid, Pantethine helps to support healthy serum lipid levels.* Pantethine is also important for healthy cardiovascular function through its antioxidant activity.*

Studies

Evans M, Rumberger JA, Azumano I, Napolitano JJ, Citrolo D, Kamiya T. Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation. Vasc Health Risk Manag. 2014 Feb 27;10:89-100. doi: 10.2147/VHRM.S57116. eCollection 2014.
See the study on PubMed »

Rumberger JA, Napolitano J, Azumano I, Kamiya T, Evans M. Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation. Nutr Res. 2011 Aug;31(8):608-15. doi: 10.1016/j.nutres.2011.08.001.
See the study on PubMed »

McRae, M. Treatment of hyperlipoproteinemia with pantethine: a review and analysis of efficacy and tolerability. 2004
See the article abstract on nrjournal.com » 

McCarty, M.F., Inhibition of acetyl-CoA carboxylase by cystamine may mediate the hypotriglyceridemic activity of pantethine. Medical Hypotheses, 2001. 56(3): p. 314-317.

Kelly, G.S., Pantethine: A Review of its Biochemistry and Therapeutic Applications. Altern Med Rev, 1997. 2(5): p. 365-376.

Arsenio, L., et al., Effectiveness of long-term treatment with pantethine in patients with dyslipidemia. Clinical Therapeutics, 1986. 8(5): p. 537-545.
http://www.ncbi.nlm.nih.gov/pubmed/3094958

Murai, A., et al., The effects of pantethine on lipid and lipoprotein abnormalities in survivors of cerebral infarction. Artery, 1983. 12(4): p. 234-243.
http://www.ncbi.nlm.nih.gov/pubmed/3935096

Maggi, G.C., C. Donati, and G. Criscuoli, Pantethine: A physiological lipomodulating agent, in the treatment of hyperlipidemias. Current Therapeutic research, 1982. 32(3): p. 380-386.

Bertolini, S., et al., Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children. International Journal of Clinical Pharmacology, Therapy and Toxiocology, 1986. 24(11): p. 630-637.

Gaddi, A., et al., Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia. Atherosclerosis, 1984. 50(1): p. 73-83.

Prisco, D., et al., Effect of oral treatment with pantethine on platelet and plasma phospholipids in IIa hyperlipoproteinemia. Angiology, 1987. 38(3): p. 241-7.

Cighetti, G., et al., Effects of pantethine on cholesterol synthesis from mevalonate in isolated rat hepatocytes. Atheroclerosis, 1986. 60: p. 67-77.

Wittwer, C.T., et al., Pantethine lipomodulation: evidence for cysteamine mediation in vitro and in vivo. Atheroclerosis, 1987. 68: p. 41-49.